Abstract
The treatment of sarcoma urgently requires new, innovative therapeutic strategies. The most recent improvements in the cure of patients with localized disease have been achieved by dose-intensification, in turn paying the price of acute severe toxicity and secondary malignancies. Keeping side-effects to a minimum is an important goal for pediatric patients and this may be achieved by combining standard cytotoxic chemotherapy with targeted approaches. In addition, after first-line therapy, very limited treatment options remain for patients with disease progression, who, like patients with metastasis at diagnosis, are in urgent need of more effective drugs. The present review highlights key examples of target identification in bone sarcomas, including chimeric oncoproteins, insulin-like growth factor receptor (IGF-IR), and tumor/ microenvironment interactions. The review identifies questions and concerns that still need to be addressed before proceeding to safe clinical trials with agents against these promising new targets.
Keywords: Osteosarcoma, ewing's sarcoma, EWS-FLI1, IGF-IR, chemotherapy, bisphosphonates
Current Cancer Drug Targets
Title: Targeted Therapies in Bone Sarcomas
Volume: 9 Issue: 7
Author(s): K. Scotlandi, P. Picci and H. Kovar
Affiliation:
Keywords: Osteosarcoma, ewing's sarcoma, EWS-FLI1, IGF-IR, chemotherapy, bisphosphonates
Abstract: The treatment of sarcoma urgently requires new, innovative therapeutic strategies. The most recent improvements in the cure of patients with localized disease have been achieved by dose-intensification, in turn paying the price of acute severe toxicity and secondary malignancies. Keeping side-effects to a minimum is an important goal for pediatric patients and this may be achieved by combining standard cytotoxic chemotherapy with targeted approaches. In addition, after first-line therapy, very limited treatment options remain for patients with disease progression, who, like patients with metastasis at diagnosis, are in urgent need of more effective drugs. The present review highlights key examples of target identification in bone sarcomas, including chimeric oncoproteins, insulin-like growth factor receptor (IGF-IR), and tumor/ microenvironment interactions. The review identifies questions and concerns that still need to be addressed before proceeding to safe clinical trials with agents against these promising new targets.
Export Options
About this article
Cite this article as:
Scotlandi K., Picci P. and Kovar H., Targeted Therapies in Bone Sarcomas, Current Cancer Drug Targets 2009; 9 (7) . https://dx.doi.org/10.2174/156800909789760410
DOI https://dx.doi.org/10.2174/156800909789760410 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Parallel Analysis of v-Src Mutant Protein Function Using Reverse Transfection Cell Arrays
Combinatorial Chemistry & High Throughput Screening Long-circulating Targeted Nanoparticles for Cancer Therapy
Current Nanoscience Ligand-modified Biopolymeric Nanoparticles as Efficient Tools for Targeted Cancer Therapy
Current Pharmaceutical Design Recent Advances in Diagnostic and Therapeutic Approaches for Breast Cancer: A Comprehensive Review
Current Pharmaceutical Design Mesenchymal Stromal Cell Therapy for Cardio Renal Disorders
Current Pharmaceutical Design Src Tyrosine Kinase Inhibition Suppresses Lymphangiogenesis In Vitro and In Vivo
Current Cancer Drug Targets Therapeutic Outcomes in AIDS-Associated Kaposi's Sarcoma Patients on Antiretroviral Therapy Treated with Chemotherapy at Two Tertiary Hospitals in Lusaka, Zambia
Current HIV Research YB-1 Activities in Oncogenesis: Transcription and Translation
Current Cancer Therapy Reviews Current Status of the Non-nucleoside Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Type 1
Current Topics in Medicinal Chemistry FDG-PET in Tuberculosis
Current Molecular Imaging (Discontinued) Protective Immunity in Humans: A Glimpse Provided by the Analysis of Herpesvirus-Specific T Cells in Health and Disease
Current Immunology Reviews (Discontinued) Transport Mechanism-Based Drug Molecular Design: Novel Camptothecin Analogues to Circumvent ABCG2-associated Drug Resistance of Human Tumor Cells
Current Pharmaceutical Design Adipose-Derived Stromal/Stem Cells (ASC) in Regenerative Medicine: Pharmaceutical Applications
Current Pharmaceutical Design Techniques and Strategies to Analyze Neural Progenitor Cell Migration
Current Pharmaceutical Biotechnology HIV-2 Infection and Chemokine Receptors Usage - Clues to Reduced Virulence of HIV-2
Current HIV Research Recent Advances in Small-Molecule HIV-1 Integrase Inhibitors
Current Medicinal Chemistry Heat Shock Protein 90 Inhibitors in Oncology
Current Proteomics Molecular Imaging of Matrix Metalloproteinases In Vivo Using Small Molecule Inhibitors for SPECT and PET
Current Medicinal Chemistry Targeting the EGFR Pathway for Cancer Therapy
Current Medicinal Chemistry Nanocarriers Conjugated with Cell Penetrating Peptides: New Trojan Horses by Modern Ulysses
Current Pharmaceutical Biotechnology